MutoS, HataM, TaniguchiJ, TsuruokaS, MoriwakiK, SaitouM, et al.: Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc Natl Acad Sci U S A107: 8011–8016, 201010.1073/pnas.0912901107
MutoS, HataM, TaniguchiJ, TsuruokaS, MoriwakiK, SaitouM, : Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc Natl Acad Sci U S A107: 8011–8016, 201010.1073/pnas.091290110710.1073/pnas.0912901107)| false
CurryJN, YuASL: Paracellular calcium transport in the proximal tubule and the formation of kidney stones. Am J Physiol Renal Physiol316: F966–F969, 201910.1152/ajprenal.00519.2018
CurryJN, YuASL: Paracellular calcium transport in the proximal tubule and the formation of kidney stones. Am J Physiol Renal Physiol316: F966–F969, 201910.1152/ajprenal.00519.201810.1152/ajprenal.00519.2018)| false
CurryJN, SauretteM, AskariM, PeiL, FillaMB, BeggsMR, et al.: Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease. J Clin Invest130: 1948–1960, 202010.1172/JCI127750
CurryJN, SauretteM, AskariM, PeiL, FillaMB, BeggsMR, : Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease. J Clin Invest130: 1948–1960, 202010.1172/JCI12775010.1172/JCI127750)| false
KonradM, SchallerA, SeelowD, PandeyAV, WaldeggerS, LesslauerA, et al.: Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet79: 949–957, 200610.1086/508617
KonradM, SchallerA, SeelowD, PandeyAV, WaldeggerS, LesslauerA, : Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet79: 949–957, 200610.1086/50861710.1086/508617)| false
GongY, ReniguntaV, HimmerkusN, ZhangJ, ReniguntaA, BleichM, et al.: Claudin-14 regulates renal Ca(+)(+) transport in response to CaSR signalling via a novel microRNA pathway. EMBO J31: 1999–2012, 201210.1038/emboj.2012.49
ThorleifssonG, HolmH, EdvardssonV, WaltersGB, StyrkarsdottirU, GudbjartssonDF, et al.: Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet41: 926–930, 200910.1038/ng.404PubMed
ThorleifssonG, HolmH, EdvardssonV, WaltersGB, StyrkarsdottirU, GudbjartssonDF, : Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet41: 926–930, 200910.1038/ng.404PubMed10.1038/ng.404)| false
GongY, HouJClaudins in barrier and transport function-the kidney. Pflugers Arch469: 105–113, 201710.1007/s00424-016-1906-610.1007/s00424-016-1906-6)| false
RiccardiD, ValentiG: Localization and function of the renal calcium-sensing receptor. Nat Rev Nephrol12: 414–425, 201610.1038/nrneph.2016.59PubMed10.1038/nrneph.2016.59)| false
RanieriM: Renal Ca(2+) and water handling in response to calcium sensing receptor signaling: Physiopathological aspects and role of casr-regulated microRNAs. Int J Mol Sci20: 5341, 201910.3390/ijms20215341
RanieriM: Renal Ca(2+) and water handling in response to calcium sensing receptor signaling: Physiopathological aspects and role of casr-regulated microRNAs. Int J Mol Sci20: 5341, 201910.3390/ijms2021534110.3390/ijms20215341)| false
Bazúa-ValentiS, Rojas-VegaL, Castaneda-BuenoM, Barrera-ChimalJ, BautistaR, Cervantes-PerezLG, et al.: The calcium-sensing receptor increases activity of the renal NCC through the WNK4-SPAK pathway. J Am Soc Nephrol29: 1838–1848, 201810.1681/ASN.2017111155
Bazúa-ValentiS, Rojas-VegaL, Castaneda-BuenoM, Barrera-ChimalJ, BautistaR, Cervantes-PerezLG, : The calcium-sensing receptor increases activity of the renal NCC through the WNK4-SPAK pathway. J Am Soc Nephrol29: 1838–1848, 201810.1681/ASN.201711115510.1681/ASN.2017111155)| false
TalmageRV, MatthewsJL, MobleyHT, LesterGE: Calcium homeostasis and bone surface proteins, a postulated vital process for plasma calcium control. J Musculoskelet Neuronal Interact3: 194–200, 2003PubMed
TalmageRV, MatthewsJL, MobleyHT, LesterGE: Calcium homeostasis and bone surface proteins, a postulated vital process for plasma calcium control. J Musculoskelet Neuronal Interact3: 194–200, 2003PubMed)| false
RenkemaKY, NijenhuisT, van der EerdenBC, van der KempAW, WeinansH, van LeeuwenJP, et al.: Hypervitaminosis D mediates compensatory Ca2+ hyperabsorption in TRPV5 knockout mice. J Am Soc Nephrol16: 3188–3195, 200510.1681/ASN.2005060632PubMed
RenkemaKY, NijenhuisT, van der EerdenBC, van der KempAW, WeinansH, van LeeuwenJP, : Hypervitaminosis D mediates compensatory Ca2+ hyperabsorption in TRPV5 knockout mice. J Am Soc Nephrol16: 3188–3195, 200510.1681/ASN.2005060632PubMed10.1681/ASN.2005060632)| false
BaronR, KneisselM: WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med19: 179–192, 201310.1038/nm.3074PubMed10.1038/nm.3074)| false
RyanZC, KethaH, McNultyMS, McGee-LawrenceM, CraigTA, GrandeJP, et al.: Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A110: 6199–6204, 201310.1073/pnas.1221255110
RyanZC, KethaH, McNultyMS, McGee-LawrenceM, CraigTA, GrandeJP, : Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A110: 6199–6204, 201310.1073/pnas.122125511010.1073/pnas.1221255110)| false
van der WijstJ, TutakhelOAZ, BosC, DanserAHJ, HoornEJ, HoenderopJGJ, et al.: Effects of a high-sodium/low-potassium diet on renal calcium, magnesium, and phosphate handling. Am J Physiol Renal Physiol315: F110–F122, 201810.1152/ajprenal.00379.2017PubMed
van der WijstJ, TutakhelOAZ, BosC, DanserAHJ, HoornEJ, HoenderopJGJ, : Effects of a high-sodium/low-potassium diet on renal calcium, magnesium, and phosphate handling. Am J Physiol Renal Physiol315: F110–F122, 201810.1152/ajprenal.00379.2017PubMed10.1152/ajprenal.00379.2017)| false
Imenez SilvaPH, Katamesh-BenabbasC, ChanK, Pastor ArroyoEM, KnöpfelT, BettoniC, et al.: The proton-activated ovarian cancer G protein-coupled receptor 1 (OGR1) is responsible for renal calcium loss during acidosis. Kidney Int97: 920–933, 202010.1016/j.kint.2019.12.006PubMed
Imenez SilvaPH, Katamesh-BenabbasC, ChanK, Pastor ArroyoEM, KnöpfelT, BettoniC, : The proton-activated ovarian cancer G protein-coupled receptor 1 (OGR1) is responsible for renal calcium loss during acidosis. Kidney Int97: 920–933, 202010.1016/j.kint.2019.12.006PubMed10.1016/j.kint.2019.12.006)| false
KhalilR, KimNR, JardiF, VanderschuerenD, ClaessensF, DecallonneB: Sex steroids and the kidney: role in renal calcium and phosphate handling. Mol Cell Endocrinol465: 61–72, 201810.1016/j.mce.2017.11.011PubMed
KhalilR, KimNR, JardiF, VanderschuerenD, ClaessensF, DecallonneB: Sex steroids and the kidney: role in renal calcium and phosphate handling. Mol Cell Endocrinol465: 61–72, 201810.1016/j.mce.2017.11.011PubMed10.1016/j.mce.2017.11.011)| false
LinPH, JianCY, ChouJC, ChenCW, ChenCC, SoongC, et al.: Induction of renal senescence marker protein-30 (SMP30) expression by testosterone and its contribution to urinary calcium absorption in male rats. Sci Rep6: 32085, 201610.1038/srep32085
LinPH, JianCY, ChouJC, ChenCW, ChenCC, SoongC, : Induction of renal senescence marker protein-30 (SMP30) expression by testosterone and its contribution to urinary calcium absorption in male rats. Sci Rep6: 32085, 201610.1038/srep3208510.1038/srep32085)| false
BeggsMR, AppelI, SvenningsenP, SkjødtK, AlexanderRT, DimkeH: Expression of transcellular and paracellular calcium and magnesium transport proteins in renal and intestinal epithelia during lactation. Am J Physiol Renal Physiol313: F629–F640, 201710.1152/ajprenal.00680.2016PubMed
BeggsMR, AppelI, SvenningsenP, SkjødtK, AlexanderRT, DimkeH: Expression of transcellular and paracellular calcium and magnesium transport proteins in renal and intestinal epithelia during lactation. Am J Physiol Renal Physiol313: F629–F640, 201710.1152/ajprenal.00680.2016PubMed10.1152/ajprenal.00680.2016)| false
HouJ, ReniguntaV, NieM, SunqA, HimmerkusN, QuintanovaC, et al.: Phosphorylated claudin-16 interacts with Trpv5 and regulates transcellular calcium transport in the kidney. Proc Natl Acad Sci U S A116: 19176–19186, 201910.1073/pnas.1902042116
HouJ, ReniguntaV, NieM, SunqA, HimmerkusN, QuintanovaC, : Phosphorylated claudin-16 interacts with Trpv5 and regulates transcellular calcium transport in the kidney. Proc Natl Acad Sci U S A116: 19176–19186, 201910.1073/pnas.190204211610.1073/pnas.1902042116)| false
KompatscherA, de BaaijJHF, AboudehenK, FarahaniS, van SonLHJ, MilatzS, et al.: Transcription factor HNF1β regulates expression of the calcium-sensing receptor in the thick ascending limb of the kidney. Am J Physiol Renal Physiol315: F27–F35, 201810.1152/ajprenal.00601.2017PubMed
KompatscherA, de BaaijJHF, AboudehenK, FarahaniS, van SonLHJ, MilatzS, : Transcription factor HNF1β regulates expression of the calcium-sensing receptor in the thick ascending limb of the kidney. Am J Physiol Renal Physiol315: F27–F35, 201810.1152/ajprenal.00601.2017PubMed10.1152/ajprenal.00601.2017)| false
BrillAL, EhrlichBE: Polycystin 2: A calcium channel, channel partner, and regulator of calcium homeostasis in ADPKD. Cell Signal66: 109490, 202010.1016/j.cellsig.2019.109490
Di MiseA, TammaG, RanieriM, CentroneM, van den HeuvelL, MekahliD, et al.: Activation of calcium-sensing receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells. Sci Rep8: 5704, 201810.1038/s41598-018-23732-5
Di MiseA, TammaG, RanieriM, CentroneM, van den HeuvelL, MekahliD, : Activation of calcium-sensing receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells. Sci Rep8: 5704, 201810.1038/s41598-018-23732-510.1038/s41598-018-23732-5)| false
Di MiseA, RanieriM, CentroneM, VenneriM, TammaG, ValentiD, et al.: Activation of the calcium-sensing receptor corrects the impaired mitochondrial energy status observed in renal polycystin-1 knockdown cells modeling autosomal dominant polycystic kidney disease. Front Mol Biosci5: 77, 201810.3389/fmolb.2018.00077
Di MiseA, RanieriM, CentroneM, VenneriM, TammaG, ValentiD, : Activation of the calcium-sensing receptor corrects the impaired mitochondrial energy status observed in renal polycystin-1 knockdown cells modeling autosomal dominant polycystic kidney disease. Front Mol Biosci5: 77, 201810.3389/fmolb.2018.0007710.3389/fmolb.2018.00077)| false
IlatovskayaDV, BlassG, PalyginO, LevchenkoV, PavlovTS, GrzybowskiMN, et al.: A NOX4/TRPC6 pathway in podocyte calcium regulation and renal damage in diabetic kidney disease. J Am Soc Nephrol29: 1917–1927, 201810.1681/ASN.2018030280
FerrettiAP, BhargavaR, DahanS, TsokosMG, TsokosGC: Calcium/calmodulin kinase IV controls the function of both T cells and kidney resident cells. Front Immunol9: 2113, 201810.3389/fimmu.2018.02113
FerrettiAP, BhargavaR, DahanS, TsokosMG, TsokosGC: Calcium/calmodulin kinase IV controls the function of both T cells and kidney resident cells. Front Immunol9: 2113, 201810.3389/fimmu.2018.0211310.3389/fimmu.2018.02113)| false
IchinoseK, RauenT, JuangYT, Kis-TothK, MizuiM, KogaT, et al.: Cutting edge: Calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J Immunol187: 5500–5504, 201110.4049/jimmunol.1102357
IchinoseK, RauenT, JuangYT, Kis-TothK, MizuiM, KogaT, : Cutting edge: Calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J Immunol187: 5500–5504, 201110.4049/jimmunol.110235710.4049/jimmunol.1102357)| false
IchinoseK, UshigusaT, NishinoA, NakashimaY, SuzukiT, HoraiY, et al.: Lupus nephritis IgG induction of calcium/calmodulin-dependent protein kinase IV expression in podocytes and alteration of their function. Arthritis Rheumatol68: 944–952, 201610.1002/art.39499
IchinoseK, UshigusaT, NishinoA, NakashimaY, SuzukiT, HoraiY, : Lupus nephritis IgG induction of calcium/calmodulin-dependent protein kinase IV expression in podocytes and alteration of their function. Arthritis Rheumatol68: 944–952, 201610.1002/art.3949910.1002/art.39499)| false
SpiegelDM, BradyK: Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int81: 1116–1122, 201210.1038/ki.2011.490
SpiegelDM, BradyK: Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int81: 1116–1122, 201210.1038/ki.2011.49010.1038/ki.2011.490)| false
ShroffR, FewtrellM, HeuserA, KolevicaA, LalayiannisA, McAlisterL, et al.: Naturally occurring stable calcium isotope ratios in body compartments provide a novel biomarker of bone mineral balance in children and young adults. J Bone Miner Res202010.1002/jbmr.4158PubMed
ShroffR, FewtrellM, HeuserA, KolevicaA, LalayiannisA, McAlisterL, : Naturally occurring stable calcium isotope ratios in body compartments provide a novel biomarker of bone mineral balance in children and young adults. J Bone Miner Res202010.1002/jbmr.4158PubMed)| false
RamalhoJ, PetrilloEM, TakeichiAPM, MoysesRMA, TitanSM: Calcitriol and FGF-23, but neither PTH nor sclerostin, are associated with calciuria in CKD. Int Urol Nephrol51: 1823–1829, 201910.1007/s11255-019-02215-0PubMed
RamalhoJ, PetrilloEM, TakeichiAPM, MoysesRMA, TitanSM: Calcitriol and FGF-23, but neither PTH nor sclerostin, are associated with calciuria in CKD. Int Urol Nephrol51: 1823–1829, 201910.1007/s11255-019-02215-0PubMed10.1007/s11255-019-02215-0)| false
TaylorJM, KienekerLM, de BorstMH, VisserST, KemaIP, BakkerSJL, et al.: Urinary calcium excretion and risk of chronic kidney disease in the general population. Kidney Int Rep2: 366–379, 201710.1016/j.ekir.2016.12.007
TaylorJM, KienekerLM, de BorstMH, VisserST, KemaIP, BakkerSJL, : Urinary calcium excretion and risk of chronic kidney disease in the general population. Kidney Int Rep2: 366–379, 201710.1016/j.ekir.2016.12.00710.1016/j.ekir.2016.12.007)| false
MizushiriS, DaimonM, MurakamiH, KambaA, OsonoiS, YamaichiM, et al.: Lower serum calcium levels are a risk factor for a decrease in eGFR in a general non-chronic kidney disease population. Sci Rep8: 14213, 201810.1038/s41598-018-32627-4
MizushiriS, DaimonM, MurakamiH, KambaA, OsonoiS, YamaichiM, : Lower serum calcium levels are a risk factor for a decrease in eGFR in a general non-chronic kidney disease population. Sci Rep8: 14213, 201810.1038/s41598-018-32627-410.1038/s41598-018-32627-4)| false
FreesS, BreukschI, HaberT, BauerHK, Chavez-MunozC, RavenP, et al.: Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma. Oncotarget9: 15766–15779, 201810.18632/oncotarget.24607
BodyJJ, BoneHG, de BoerRH, StopeckA, Van PoznakC, DamiãoR, et al.: Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer51: 1812–1821, 201510.1016/j.ejca.2015.05.016PubMed
BodyJJ, BoneHG, de BoerRH, StopeckA, Van PoznakC, DamiãoR, : Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer51: 1812–1821, 201510.1016/j.ejca.2015.05.016PubMed10.1016/j.ejca.2015.05.016)| false
IshikawaK, NagaiT, SakamotoK, OharaK, EguroT, ItoH, et al.: High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag12: 1831–1840, 201610.2147/TCRM.S123172
IshikawaK, NagaiT, SakamotoK, OharaK, EguroT, ItoH, : High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Ther Clin Risk Manag12: 1831–1840, 201610.2147/TCRM.S12317210.2147/TCRM.S123172)| false
MiyaokaD, ImanishiY, OharaM, HayashiN, NagataY, YamadaS, et al.: Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int30: 241–249, 201910.1007/s00198-018-4688-1PubMed
MiyaokaD, ImanishiY, OharaM, HayashiN, NagataY, YamadaS, : Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int30: 241–249, 201910.1007/s00198-018-4688-1PubMed10.1007/s00198-018-4688-1)| false
ThongprayoonC, AcharyaP, AcharyaC, ChenbhanichJ, BathiniT, BoonphengB, et al.: Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int29: 1737–1745, 201810.1007/s00198-018-4533-6PubMed
ThongprayoonC, AcharyaP, AcharyaC, ChenbhanichJ, BathiniT, BoonphengB, : Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies. Osteoporos Int29: 1737–1745, 201810.1007/s00198-018-4533-6PubMed10.1007/s00198-018-4533-6)| false
ThongprayoonC, AcharyaP, AeddulaNR, Torres-OrtizA, BathiniT, SharmaK, et al.: Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis. Arch Osteoporos14: 35, 201910.1007/s11657-019-0587-0PubMed
ThongprayoonC, AcharyaP, AeddulaNR, Torres-OrtizA, BathiniT, SharmaK, : Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis. Arch Osteoporos14: 35, 201910.1007/s11657-019-0587-0PubMed10.1007/s11657-019-0587-0)| false
NanmokuK, ShinzatoT, KuboT, ShimizuT, YagisawaT: Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients. Clin Nephrol92: 1–8, 201910.5414/CN109723PubMed
NanmokuK, ShinzatoT, KuboT, ShimizuT, YagisawaT: Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients. Clin Nephrol92: 1–8, 201910.5414/CN109723PubMed10.5414/CN109723)| false
HoLY, WongPN, SinHK, WongYY, LoKC, ChanSF, et al.: Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol18: 12, 201710.1186/s12882-016-0421-5
HoLY, WongPN, SinHK, WongYY, LoKC, ChanSF, : Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol18: 12, 201710.1186/s12882-016-0421-510.1186/s12882-016-0421-5)| false
GeY, YangG, WangN, ZhaX, YuX, MaoH, et al.: Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Int Urol Nephrol51: 1443–1449, 201910.1007/s11255-019-02217-yPubMed
GeY, YangG, WangN, ZhaX, YuX, MaoH, : Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Int Urol Nephrol51: 1443–1449, 201910.1007/s11255-019-02217-yPubMed10.1007/s11255-019-02217-y)| false
KoWC, LiuCL, LeeJJ, LiuTP, WuCJ, ChengSP: Osteocalcin is an Independent Predictor for Hungry Bone Syndrome After Parathyroidectomy. World J Surg44: 795–802, 202010.1007/s00268-019-05251-0PubMed
KoWC, LiuCL, LeeJJ, LiuTP, WuCJ, ChengSP: Osteocalcin is an Independent Predictor for Hungry Bone Syndrome After Parathyroidectomy. World J Surg44: 795–802, 202010.1007/s00268-019-05251-0PubMed10.1007/s00268-019-05251-0)| false
WangM, ChenB, ZouX, WeiT, GongR, ZhuJ, et al.: A nomogram to predict hungry bone syndrome after parathyroidectomy in patients with secondary hyperparathyroidism. J Surg Res255: 33–41, 202010.1016/j.jss.2020.05.036PubMed
WangM, ChenB, ZouX, WeiT, GongR, ZhuJ, : A nomogram to predict hungry bone syndrome after parathyroidectomy in patients with secondary hyperparathyroidism. J Surg Res255: 33–41, 202010.1016/j.jss.2020.05.036PubMed10.1016/j.jss.2020.05.036)| false
WongJ, FuWH, LimELA, NgCFJ, ChoongHL: Hungry bone syndrome after parathyroidectomy in end-stage renal disease patients: review of an alkaline phosphatase-based treatment protocol. Int Urol Nephrol52: 557–564, 202010.1007/s11255-020-02387-0PubMed
WongJ, FuWH, LimELA, NgCFJ, ChoongHL: Hungry bone syndrome after parathyroidectomy in end-stage renal disease patients: review of an alkaline phosphatase-based treatment protocol. Int Urol Nephrol52: 557–564, 202010.1007/s11255-020-02387-0PubMed10.1007/s11255-020-02387-0)| false
FloegeJ, TsirtsonisK, IlesJ, DruekeTB, ChertowGM, ParfreyP: Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int93: 1475–1482, 201810.1016/j.kint.2017.12.014PubMed
FloegeJ, TsirtsonisK, IlesJ, DruekeTB, ChertowGM, ParfreyP: Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int93: 1475–1482, 201810.1016/j.kint.2017.12.014PubMed10.1016/j.kint.2017.12.014)| false
PalmerSC, MavridisD, JohnsonDW, TonelliM, RuospoM, StrippoliGFM: Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: A systematic review and network meta-analysis. Am J Kidney Dis76: 321–330, 202010.1053/j.ajkd.2020.02.439PubMed
PalmerSC, MavridisD, JohnsonDW, TonelliM, RuospoM, StrippoliGFM: Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: A systematic review and network meta-analysis. Am J Kidney Dis76: 321–330, 202010.1053/j.ajkd.2020.02.439PubMed10.1053/j.ajkd.2020.02.439)| false
LouieKS, ErhardC, WheelerDC, StenvinkelP, FouquerayB, FloegeJ: Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. J Nephrol33: 803–816, 202010.1007/s40620-019-00686-z
LouieKS, ErhardC, WheelerDC, StenvinkelP, FouquerayB, FloegeJ: Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. J Nephrol33: 803–816, 202010.1007/s40620-019-00686-z10.1007/s40620-019-00686-z)| false
EvenepoelP, ShroffR: Facing cinacalcet-induced hypocalcemia: sit back and relax?Kidney Int93: 1275–1277, 201810.1016/j.kint.2018.01.038PubMed10.1016/j.kint.2018.01.038)| false
OkE, AsciG, BayraktarogluS, TozH, OzkahyaM, YilmazM, et al.: Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis. J Am Soc Nephrol27: 2475–2486, 201610.1681/ASN.2015030268
OkE, AsciG, BayraktarogluS, TozH, OzkahyaM, YilmazM, : Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis. J Am Soc Nephrol27: 2475–2486, 201610.1681/ASN.201503026810.1681/ASN.2015030268)| false
YoshikawaM, TakaseO, TsujimuraT, SanoE, HayashiM, TakatoT, et al.: Long-term effects of low calcium dialysates on the serum calcium levels during maintenance hemodialysis treatments: A systematic review and meta-analysis. Sci Rep8: 5310, 201810.1038/s41598-018-23658-y
HamrounA, LenainR, Bui NguyenL, ChamleyP, LoridantS, NeugebauerY, et al.: Hypercalcemia is common during Pneumocystis pneumonia in kidney transplant recipients. Sci Rep9: 12508, 201910.1038/s41598-019-49036-w
ChallenerD, SalehAO: A case of hypercalcemia and antibiotic-related acute kidney injury following implantation of antibiotic impregnated calcium sulfate beads. Ann Lab Med39: 507–508, 201910.3343/alm.2019.39.5.507
ChallenerD, SalehAO: A case of hypercalcemia and antibiotic-related acute kidney injury following implantation of antibiotic impregnated calcium sulfate beads. Ann Lab Med39: 507–508, 201910.3343/alm.2019.39.5.50710.3343/alm.2019.39.5.507)| false
ManfroAG, LutzkyM, DoraJM, KalilMAS, ManfroRC: Case reports of hypercalcemia and chronic renal disease due to cosmetic injections of polymethylmethacrylate (PMMA) [published online ahead of print August 10, 2020]. J Bras Nefrol10.1590/2175-8239-JBN-2020-0044PubMed
ManfroAG, LutzkyM, DoraJM, KalilMAS, ManfroRC: Case reports of hypercalcemia and chronic renal disease due to cosmetic injections of polymethylmethacrylate (PMMA) [published online ahead of print August 10, 2020]. J Bras Nefrol10.1590/2175-8239-JBN-2020-0044PubMed)| false
StewartAF, AdlerM, ByersCM, SegreGV, BroadusAE: Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med306: 1136–1140, 198210.1056/NEJM198205133061903PubMed
StewartAF, AdlerM, ByersCM, SegreGV, BroadusAE: Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med306: 1136–1140, 198210.1056/NEJM198205133061903PubMed10.1056/NEJM198205133061903)| false
SpatzJM, FieldsEE, YuEW, Divieti PajevicP, BouxseinML, SibongaJD, et al.: Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab97: E1736–E1740, 201210.1210/jc.2012-1579
OsipovB, EmamiAJ, ChristiansenBA: Systemic bone loss after fracture. Clin Rev Bone Miner Metab16: 116–130, 201810.1007/s12018-018-9253-010.1007/s12018-018-9253-0)| false
ZerwekhJE, RumlLA, GottschalkF, PakCY: The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Miner Res13: 1594–1601, 199810.1359/jbmr.1998.13.10.1594PubMed
ZerwekhJE, RumlLA, GottschalkF, PakCY: The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Miner Res13: 1594–1601, 199810.1359/jbmr.1998.13.10.1594PubMed10.1359/jbmr.1998.13.10.1594)| false
WangPL, MeyerMM, OrloffSL, AndersonS: Bone resorption and “relative” immobilization hypercalcemia with prolonged continuous renal replacement therapy and citrate anticoagulation. Am J Kidney Dis44: 1110–1114, 200410.1053/j.ajkd.2004.09.001PubMed
